Patent ID: 11878011
Assignee: REDHILL BIOPHARMA LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating patients who are positive for Helicobacter pylori infection comprising:
determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight;
determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and
administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient
wherein the rifabutin-based triple therapy comprises a plurality of fixed-dose combination formulations which provide a total daily dose of 150 mg rifabutin, 3,000 mg amoxicillin, and 120 mg omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, and
wherein each fixed-dose combination formulation comprises between 36 and 40 immediate release minitablets, the immediate release minitablets comprising both amoxicillin and rifabutin, and between 32 and 36 enteric-coated omeprazole minitablets.